Cevimeline Hydrochloride Patent Expiration

Cevimeline Hydrochloride is Used for managing symptoms of Sjögren's syndrome. It was first introduced by Cosette Pharmaceuticals Inc in its drug Evoxac on Jan 11, 2000. 9 different companies have introduced drugs containing Cevimeline Hydrochloride.


Cevimeline Hydrochloride Patents

Given below is the list of patents protecting Cevimeline Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Evoxac US5340821 Composition and method for treating Sjoegren syndrome disease Jul 07, 2013

(Expired)

Cosette



Cevimeline Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Cevimeline Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Cevimeline Hydrochloride. The first generic version for Cevimeline Hydrochloride was by Apotex Inc and was approved on Aug 25, 2011. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Sep 20, 2024.

Given below is the list of companies who have filed for Cevimeline Hydrochloride generic, along with the locations of their manufacturing plants worldwide.